Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Self-Amplifying mRNA COVID-19 Booster Vaccine in People with HIV
jRCT1031250429Active, not recruiting
- Start
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Trial of kofidameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by none. Primary endpoint: SARS-CoV-2 Neutralizing Antibody (XEC, LP8.1). Started Nov 2025; status: active, not recruiting.
02
Drugs
kofidameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1031250429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250429.